Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
One of Bitcoin’s most prominent investors is making a new monster bet.
Cybin Corp acquires Adelia Therapeutics in an all-stock transaction valued at CAD$20.2 million.
Numinus announces a bought deal financing at CAD$0.68 cents.
ATAI Life Science's IPO in 2021 is expected to be another big industry catalyst. But one company that might NOT benefit is Compass Pathways.
Entheon discusses its new strategic investment in Wonder Scientific.
Roughly $500 million dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.
Numinus' Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.
Mind Cure stock is now much more easily accessible for U.S.-based investors.
Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now